- Azenta appointed Trey Martin as president of its Multiomics business, effective April 6, 2026.
- Martin will lead Multiomics operations, reporting to CEO John Marotta.
- Ginger Zhou stepped down as Multiomics president, staying on as an adviser through November 2026.
- Martin most recently served as CEO and a board member at Maravai Life Sciences.
- He previously held senior roles at Danaher, including senior vice president of Genomic Medicines, president of Integrated DNA Technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azenta Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE28212) on April 07, 2026, and is solely responsible for the information contained therein.
Comments